[HTML][HTML] Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
JP Lalezari, K Henry, M O'Hearn… - … England Journal of …, 2003 - Mass Medical Soc
Background The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized,
open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV …
open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV …
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
JP Lalezari, K Henry, M O'Hearn… - The New England …, 2003 - europepmc.org
Background The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized,
open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV …
open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV …
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
JP Lalezari, K Henry, M O'Hearn, JSG Montaner… - 2003 - cabidigitallibrary.org
Abstract Background: The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a
randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency …
randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency …
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
JP Lalezari, K Henry, M O'Hearn… - The New England …, 2003 - pubmed.ncbi.nlm.nih.gov
Background The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized,
open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV …
open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV …
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
JP Lalezari, K Henry, M O'Hearn… - … England Journal of …, 2003 - ohsu.elsevierpure.com
BACKGROUND The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a
randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency …
randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency …
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
JP Lalezari, K Henry, M O'Hearn… - New England Journal …, 2003 - experts.umn.edu
BACKGROUND The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a
randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency …
randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency …
[PDF][PDF] Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
JP Lalezari, K Henry, M O'Hearn, JSG Montaner… - N Engl J …, 2003 - researchgate.net
Patients from 48 sites in the United States, Canada, Mexico, and Brazil with at least six
months of previous treatment with agents in three classes of antiretroviral drugs, resistance …
months of previous treatment with agents in three classes of antiretroviral drugs, resistance …
[引用][C] Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
JP Lalezari, K Henry, M O'Hearn… - New England Journal …, 2003 - cir.nii.ac.jp
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South
America | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
America | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
JP Lalezari, K Henry, M O'Hearn… - New England Journal of …, 2003 - elibrary.ru
Virologic failure was defined by either a decrease from base line ofless than 0.5 log sub 10
copies per milliliter in plasma HIV-1 RNA on two or three consecutive measurements after …
copies per milliliter in plasma HIV-1 RNA on two or three consecutive measurements after …
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
JP Lalezari, K Henry, M O'Hearn… - New England Journal …, 2003 - cdr.lib.unc.edu
Background: The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized,
open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV …
open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV …